Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration

Figure 1

(a) Association of baseline visual acuity (VA) score with VA score change at 6 months. Baseline VA score was significantly associated with VA score change at 6 months (𝑃=0.015). *𝑃=0.036 (the first group was the reference). (b) Association of duration of neovascular age-related macular degeneration (AMD) with VA score change at 6 months. Duration of neovascular AMD was significantly associated with VA score change at 6 months (𝑃=0.005). *𝑃=0.005; ^†𝑃=0.007; ^‡𝑃=0.001 (the first group was the reference).

(a)

(b)